Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment With Opioids

NCT05588323 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT05588323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment With Opioids
Lead sponsor
Shionogi
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 4, 2023
Completion date
June 15, 2028
Enrollment
24 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-induced constipation (oic)